Cannabis firms have been urged to set their sights on formally registering products with the health regulator as they received fresh guidance surrounding the supply of unapproved medicine.
In a document spelling out their responsibilities under the Special Access Scheme (SAS), sponsors were told they must “take on the responsibility” of including products in the Australian Register of Therapeutic Goods (ARTG).
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.